Citing Management Turnover, 'Energized' Sales Channels, Analyst Christens Affymetrix a 'New Company' | GenomeWeb

There is "still a lot to like" about Affymetrix, according to Peter Lawson. The Mizuho Securities analyst released a note this week in which he summarized recent discussions with the management of the Santa Clara, Calif.-based microarray vendor, and reiterated the investment firm's ratng of Buy for Affymetrix's stock with a price target of $12.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.